Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM

The 30-month results of the phase 3 ATTRibute-CM trial provide the latest insight into the effects of acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM) ahead of a potential regulatory submission for the agent.

Presented during a hot line session at the European Society of Cardiology (ESC) Congress 2023, results of the trial suggest the acoramidis cohort experienced an 81% survival rate at 30 months, with additional analysis suggesting use of acoramidis was associated with a 30% reduction in risk of cardiovascular death relative to placebo therapy.¹

Stay Up To Date:

Receive the latest news and developments in treatment and care

Featured Resources

FAQs

1 The Core Members of an Amyloidosis Care Team ?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

2 What Treatment Options are Available for Amyloidosis?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

3 How is Amyloidosis Diagnosed?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.

4 What Specialists Are Involved in the Treatment of Amyloidosis?

Find resources, support groups, and organizations that offer information, assistance, and a community for Amyloidosis patients and their families.